← Back to screener

GYRE THERAPEUTICS, INC. GYRE

Rank #693 · Nasdaq · $0.4B market cap
Audited by Grant Thornton Zhitong Certified Public Accountants LLP, no going-concern flag in the latest filing.
Score
60.3
P/E
24.7
P/B
6.98
ROE
28.3%
Op. Margin
15.3%
Debt Ratio
43%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E 24.7x, P/B 6.98x. Ranks in the top 54% of the universe.

Profitability ★★★★☆
Good

ROE 28.3%. Ranks in the top 22% of the universe.

Safety ★★★★☆
Good

Debt ratio 43%. Ranks in the top 21% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Weak

Revenue decline of 6.8% year over year. Ranks in the top 79% of the universe.

Profitability is the relative strength · Growth is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$0.1B-160.9298
2012$0.1B$0.0B$0.0B$0.1B15.3122
2013$0.1B$-0.0B$-0.0B$0.1B-10.015
2014$0.1B$-0.0B$-0.0B$0.2B-14.16
2015–$-0.0B$-0.0B$-0.1B–-4
2016–$-0.0B$-0.0B$-0.1B–-35
2017–$-0.0B$-0.0B$0.0B–70
2018$0.0B$-0.0B$-0.0B$0.0B-2143.654
2019$0.0B$-0.0B$-0.0B$0.0B-563700.016
2020$0.0B$-0.1B$-0.1B$0.1B-273.425
2021$0.0B$-0.1B$-0.1B$0.1B-273.927
2022–$-0.1B$-0.1B$0.1B–19
2023$0.1B$0.0B$0.0B$0.0B9.029
2024$0.1B$-0.1B$-0.1B$-0.0B-59.3-240
2025$0.1B$0.0B$0.0B$0.1B15.343

← See the full screener